| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | Cost Comparison Standard |
| ID number | 4070 |
Project Team
| Project lead | Jeremy Powell |
Email enquiries
- If you have any queries please email tateam2@nice.org.uk
| External Assessment Group | Health Economics Research Unit and Health Services Research Unit, University of Aberdeen |
Stakeholders
| Companies sponsors | BeiGene (tislelizumab) |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Black Health Agency for Equality |
| Cancer 52 | |
| Cancer Black Care | |
| Cancer Equality | |
| GIST Cancer UK | |
| GUTS UK | |
| Heartburn Cancer UK | |
| Helen Rollason Cancer Charity | |
| Independent Cancer Patients Voice | |
| Macmillan Cancer Support | |
| Maggie’s Centres | |
| Marie Curie | |
| Ochre | |
| Oesophageal Patients Association | |
| OG Support formerly Together Support Group | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| Tenovus Cancer Care | |
| Professional groups | Association of Anaesthetists |
| Association of Cancer Physicians | |
| Association of Surgeons of Great Britain and Ireland | |
| Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland | |
| British Association of Surgical Oncology | |
| British Geriatrics Society | |
| British Institute of Radiology | |
| British Oncology Pharmacy Association | |
| British Psychosocial Oncology Society | |
| British Society of Gastroenterology | |
| Cancer Research UK | |
| Primary Care Society for Gastroenterology | |
| Royal College of Anaesthetists | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Royal College of Surgeons | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine | |
| Society and College of Radiographers | |
| UK Clinical Pharmacy Association | |
| UK Oncology Nursing Society | |
| Associated public health groups | Public Health Wales |
| UK Health Security Agency | |
| Comparator companies | Bristol Myers Squibb Pharmaceuticals (nivolumab) |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| Allied Health Professionals Federation | |
| Board of Community Health Councils in Wales | |
| British National Formulary | |
| Care Quality Commission | |
| Department of Health - Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| National Association of Primary Care | |
| National Pharmacy Association | |
| NHS Confederation | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Genomics England |
| Institute of Cancer Research | |
| MRC Clinical Trials Unit | |
| National Institute for Health Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 25 November 2024 | Invitation to participate |
| 15 July 2024 - 12 August 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4070 |
| 15 July 2024 | In progress. Scoping commencing |
| 15 July 2024 | In progress. Scoping commencing |
| 02 July 2024 | Please note that following an update from the company the timelines for this appraisal are anticipated to begin in mid-October 2024 when we will write to you about how you can get involved. |
| 02 July 2024 | Please note that following an update from the company the timelines for this appraisal are anticipated to begin in mid-October 2024 when we will write to you about how you can get involved. |
| 16 January 2024 | For information, tislelizumab has now been acquired by the company Beigene. NICE are liaising with the company regarding appropriate timelines for this appraisal and further information will be available in due course. |
| 01 August 2023 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 09 November 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 26 August 2022 | Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during early March 2023. |
For further information on our processes and methods, please see our CHTE processes and methods manual